These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12703990)

  • 1. [Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].
    Liang YJ; Fu LW; Ding Y; Xiong HY; Chen LM; Yang XP; Pan QC
    Ai Zheng; 2003 Apr; 22(4):368-71. PubMed ID: 12703990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of hydroxycamptothecin on laryngeal squamous carcinoma cell line].
    Chai LP; Su ZZ; Xian ZX
    Ai Zheng; 2003 Apr; 22(4):372-5. PubMed ID: 12703991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticancer effect of hydroxycampothecin on oral squamous carcinoma cell line].
    Ding XQ; Wang AX; Kong QY; Chen HZ; Chen Y
    Ai Zheng; 2002 Apr; 21(4):388-91. PubMed ID: 12452017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tea polyphenol inhibit on growth of human nasopharyngeal carcinoma cell and xenograft in nude mice].
    Feng GK; Xie BF; Liu ZC; Zhu XF; Ye YL
    Ai Zheng; 2002 Apr; 21(4):392-4. PubMed ID: 12452018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effects of ring-closed and ring-opened hydroxycamptothecin on oral squamous carcinoma cell line Tca8113].
    Wang AX; Li S; Ding XQ; Chen Y; Chen D
    Ai Zheng; 2005 Aug; 24(8):970-4. PubMed ID: 16086875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
    Shang BY; Shang Y; Zhen YS; Chen SZ
    Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with Rhizoma Paridis and Rhizoma Curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in H22 tumor model by increasing the plasma concentration.
    Liu Z; Li H; Fan Y; Liu Y; Man S; Yu P; Gao W
    Biomed Pharmacother; 2016 Oct; 83():627-634. PubMed ID: 27459119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
    Chauvier D; Morjani H; Manfait M
    Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer.
    Ping YH; Lee HC; Lee JY; Wu PH; Ho LK; Chi CW; Lu MF; Wang JJ
    Oncol Rep; 2006 May; 15(5):1273-9. PubMed ID: 16596197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
    Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
    J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumour effects of triptolide plus 10-hydroxycamptothecin onbladder cancer.
    Wang T; Ding Y; Yang Y; Wang Z; Gao W; Li D; Wei J; Sun Y
    Biomed Pharmacother; 2019 Jul; 115():108899. PubMed ID: 31063955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
    Kimura T
    Osaka City Med J; 2001 Jun; 47(1):33-41. PubMed ID: 11556390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.
    Qi Y; Liu G
    Drug Deliv; 2021 Dec; 28(1):171-182. PubMed ID: 33427515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells.
    Ling YH; Xu B
    Zhongguo Yao Li Xue Bao; 1993 Nov; 14(6):546-50. PubMed ID: 8010056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin.
    Tang Q; Ji F; Wang J; Guo L; Li Y; Bao Y
    Eur J Pharm Sci; 2017 Nov; 109():223-232. PubMed ID: 28822757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The synergistic antitumor effects of berberine alpha-hydroxy-beta-decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase].
    Lin J; Wang X
    Yao Xue Xue Bao; 2011 Apr; 46(4):390-4. PubMed ID: 21751491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects.
    Tang Q; Ji F; Sun W; Wang J; Guo J; Guo L; Li Y; Bao Y
    Phytomedicine; 2016 Dec; 23(14):1778-1786. PubMed ID: 27912880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
    Usui N; Matsushima K; Pilaro AM; Longo DL; Wiltrout RH
    Biotherapy; 1996; 9(4):199-208. PubMed ID: 9012539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance.
    Liu M; Chen D; Wang C; Chen X; Wen Z; Cao Y; He H
    J Drug Target; 2015; 23(9):800-5. PubMed ID: 25766079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity.
    Cai J; Luo S; Lv X; Deng Y; Huang H; Zhao B; Zhang Q; Li G
    Int J Pharm; 2019 Nov; 571():118693. PubMed ID: 31525442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.